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Abstract
Background: Bovine necrohemorrhagic enteritis is caused by Clostridium perfringens type A. Due to the rapid
progress and fatal outcome of the disease, vaccination would be of high value. In this study, C. perfringens toxins,
either as native toxins or after formaldehyde inactivation, were evaluated as possible vaccine antigens. We
determined whether antisera raised in calves against these toxins were able to protect against C. perfringens
challenge in an intestinal loop model for bovine necrohemorrhagic enteritis.
Results: Alpha toxin and perfringolysin O were identified as the most immunogenic proteins in the vaccine
preparations. All vaccines evoked a high antibody response against the causative toxins, alpha toxin and
perfringolysin O, as detected by ELISA. All antibodies were able to inhibit the activity of alpha toxin and
perfringolysin O in vitro. However, the antibodies raised against the native toxins were more inhibitory to the C.
perfringens-induced cytotoxicity (as tested on bovine endothelial cells) and only these antibodies protected against
C. perfringens challenge in the intestinal loop model.
Conclusion: Although immunization of calves with both native and formaldehyde inactivated toxins resulted in
high antibody titers against alpha toxin and perfringolysin O, only antibodies raised against native toxins protect
against C. perfringens challenge in an intestinal loop model for bovine necrohemorrhagic enteritis.
Keywords: Bovine necrohemorrhagic enteritis, Clostridium perfringens, Neutralizing antibodies, Alpha toxin,
Perfringolysin O
Background
The ubiquitous, spore forming, Gram-positive bacterium
Clostridium perfringens is considered to be the most
widespread pathogenic bacterium in the world [1–4]. It
can cause a wide range of diseases including, amongst
others, gas gangrene in man and necrohemorrhagic en-
teritis in suckling and veal calves [5–8]. Most of these
diseases follow a very rapid, often fatal course. There-
fore, curative treatment is difficult and control must rely
on preventive measures, including vaccination. Virulence
properties of different C. perfringens strains are largely de-
termined by their ability to secrete a variety of protein-
aceous toxins and enzymes, which can cause different
forms of tissue damage [2–4, 9]. Alpha toxin and perfringo-
lysin O have been identified as the principal toxins involved
in the pathogenesis of both C. perfringens-induced gas gan-
grene and bovine necrohemorrhagic enteritis [10, 11].
These toxins exert different effects in both diseases. Bovine
necrohemorrhagic enteritis is characterized by congestion
of the capillaries, hemorrhages and inflammation. This is in
contrast to gas gangrene, where these toxins lead to tissue
necrosis, thrombosis and lack of leukocyte infiltration at
the site of infection [10–12]. It is well known that humoral
antibodies against secreted proteinaceous virulence factors
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of C. perfringens can be protective, as shown in different
animal models. As the enzymes and toxins of C. perfringens
are highly destructive to tissues, vaccines against a variety
of clostridial diseases have been developed using the dena-
tured proteins [13–15]. Despite the usefulness of formalde-
hyde toxoids for other C. perfringens-associated diseases,
there is controversy about the efficacy of such vaccines for
gas gangrene, as opposed to crude toxin preparations [8,
16–18]. In addition, multivalent clostridial vaccines based
on formaldehyde inactivated exotoxins derived from culture
supernatant are commercially available for domestic live-
stock, including bovines, but no studies on their efficacy for
necrohemorrhagic enteritis in calves are available.
The objective of the present study was to evaluate
whether antibodies against C. perfringens toxins could pro-
tect against the development of necrotic lesions in the in-
testine. Therefore, calves were immunized with native C.
perfringens toxins. To evaluate whether we could eliminate
the undesired toxin activity, but conserve the immune-
protective potential, a previously described, modified for-
maldehyde treatment was also tested [19]. Also a commer-
cial formaldehyde inactivated multivalent clostridial vaccine
was used. As necrohemorrhagic enteritis in veal calves is an
unpredictable event and experimental reproduction of the
disease is difficult, the neutralizing activity of the antibodies
was evaluated in a previously developed intestinal loop
model [20]. To further unravel the mechanism of protec-
tion, the inhibitory effect of the evoked antibodies on C.
perfringens-induced cytotoxicity to bovine endothelial cells
was evaluated and the toxin-neutralizing capacity against
alpha toxin and perfringolysin O was analyzed.
Results
Western blot analysis
The proteins in the C. perfringens toxin preparation were
visualized by SDS-PAGE (Fig. 1a). In the vaccinated
calves, the production of circulating antibodies against
C. perfringens supernatant and the C. perfringens toxin
preparation was analyzed by western blot in three separ-
ate experiments (Fig. 1). No immune reaction was
detected in the sera before immunization (data not
shown). Sera obtained from calves six weeks after initial
vaccination with either native toxins or the L-lysine pro-
tected, formaldehyde inactivated toxins, revealed immu-
noreactivity towards two proteins. Immune sera from
calves vaccinated with the commercial formaldehyde
inactivated clostridial vaccine showed immunoreactivity
towards more proteins. The two proteins that were im-
munoreactive with antisera raised against all vaccine
preparations were further identified as alpha toxin and
perfringolysin O by MALDI analysis.
ELISA
In the vaccinated calves, the production of circulating
antibodies directed against alpha toxin and perfringoly-
sin O was also monitored by ELISA. No antibodies
against alpha toxin or perfringolysin O were detected in
the sera before immunization. In all calves a strong anti-
body response against both alpha toxin and perfringoly-
sin O was detected 6 weeks after initial immunization.
Calves vaccinated with the native C. perfringens toxins
showed the highest antibody titers, whereas vaccination
with formaldehyde inactivated toxins (either L-lysine
protected or commercial inactivation) resulted in a more
variable immune response (Table 1).
Protective effect of antisera against C. perfringens-induced
necrosis in an intestinal loop model
The potential of the antisera, derived after vaccination of
calves with the respective vaccines, to inhibit C. perfringens-
induced necrosis, was evaluated in an intestinal loop assay.
All positive control loops inoculated with C. perfringens
Fig. 1 Western blot analysis of the immune sera. a SDS-PAGE of the C. perfringens toxin preparation after Coomassie staining. b-d Representative
Western blots showing the immunoreactivity towards crude C. perfringens supernatants (lane 1) and the C. perfringens toxin preparation (lane 2).
The immune sera from calves vaccinated with native toxins (b) and formaldehyde inactivated, L-lysine protected C. perfringens toxins (c) detect
only two proteins, whereas the commercial formaldehyde inactivated multivalent clostridial vaccine (d) reacts with multiple proteins. The blots
shown are representative pictures of one out of three experiments
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developed necrosis. Injection of loops with C. perfringens
together with sera from naive calves (pre-immune sera)
also resulted in a high percentage of necrotic loops. Injec-
tion of C. perfringens together with antisera raised against
native toxins resulted in significantly fewer necrotic loops
as compared to the positive control loops (p < 0.001) and
the loops injected with the pre-immune sera (p < 0.01).
Antisera raised against formaldehyde inactivated toxoid
(either L-lysine protected or commercial) were unable to
significantly neutralize the necrosis-inducing activity of C.
perfringens (Figs. 2 and 3).
Neutralization of alpha toxin and perfringolysin O activity
in vitro
The inhibitory capacity of the sera towards alpha toxin
and perfringolysin O activities was further examined using
recombinant toxins. All antisera decreased the activity of
alpha toxin in vitro (Table 2). Up to a final dilution of
409.8 the antisera against the native toxins neutralized
50 % of the alpha toxin activity. To the contrary, in order
to obtain the same inhibition of alpha toxin activity, anti-
sera against L-lysine protected, formaldehyde inactivated
toxoid or against the commercial formaldehyde inacti-
vated clostridial vaccine could only be diluted up to final
dilutions of 80.47 or 22.39, respectively.
The hemolytic activity of perfringolysin O towards
equine erythrocytes in vitro was decreased by all antisera
(Table 2). Up to a final dilution of 18 either antiserum
inhibited the perfringolysin O activity completely. This
neutralizing ability of the sera was observed up to a final
dilution of 48 for the anti-native toxins antisera, a final di-
lution of 72 for the anti-L-lysine protected, formaldehyde
inactivated toxoid or a final dilution of 18 when the anti-
serum obtained after vaccination with the commercial
vaccine was used. The pre-immune sera had no effect on
the alpha toxin or perfringolysin O activity in vitro.
Neutralization of C. perfringens cytotoxicity to bovine
endothelial cells
To determine whether the cytotoxic activity of C. per-
fringens could be inhibited by the antisera to the
vaccines, C. perfringens supernatants were incubated
with serial dilutions of the antisera. Exposure of the
endothelial cells to untreated C. perfringens supernatant
resulted in 100 % cell death. More than 80 % cell viability
could be measured by pre-incubation of the C. perfringens
supernatant with a 32-fold dilution of the native toxins
antiserum. At this concentration, neither the antisera
raised against L-lysine protected, formaldehyde inactivated
toxins nor the antisera raised against the commercial for-
maldehyde inactivated clostridial vaccine had an effect on
the cytotoxicity (Table 3). The pre-immune sera had no
effect on the C. perfringens cytotoxicity.
Discussion
Necrohemorrhagic enteritis caused by C. perfringens in
suckling and veal calves is characterized by sudden
death. Due to the very rapid course of the disease, cura-
tive treatment is not possible and therefore, protection
by vaccination would be of high value. The virulence of
C. perfringens is due to the many extracellular toxins it
produces. In this study we showed that toxin neutraliz-
ing antibodies protect against C. perfringens-induced
necrotic lesions in an intestinal loop assay and are able
to prevent endothelial damage. Western blot analysis
Table 1 Calves were immunized with either a C. perfringens
toxin preparation (native toxins), L-lysine protected, formaldehyde
inactivated C. perfringens toxins (L-lysine/formaldehyde toxoid) or






Native toxins 64.44 ± 0.22 25600 ± 0
L-lysine/formaldehyde toxoid 24.26 ± 2.96 16000 ± 9600
Commercial formaldehyde vaccine 45.14 ± 20.42 4800 ± 1600
The anti-alpha toxin and perfringolysin O response was measured by ELISA.
The data represent antibody titers (mean ± standard error of the means), six
weeks after initial immunization
Fig. 2 Neutralization of the lesion-inducing potential of C. perfringens.
The graph represents the percentage of ligated intestinal loops in
which necrotic lesions were present after 5 h of incubation with sterile
culture medium (n = 20), C. perfringens alone (untreated, n = 20) or C.
perfringens in combination with naive sera (pre-immune serum, n = 60),
antiserum to C. perfringens toxins (native toxins, n = 20), formaldehyde
inactivated, L-lysine protected C. perfringens toxins (L-lysine/formaldehyde,
n= 20) and commercial formaldehyde inactivated multivalent clostridial
vaccine (commercial formaldehyde, n= 20). ** 0.001≤ p< 0.01 or
*** p< 0.001
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revealed antibodies towards alpha toxin and perfringoly-
sin O as the most abundant antibodies in the immune
sera from calves vaccinated against C. perfringens toxins.
We previously reported congestion and leakage of the ca-
pillaries as an early event in the pathogenesis of necrohe-
morrhagic enteritis as shown in an intestinal loop assay
[20]. Furthermore we showed that alpha toxin and perfrin-
golysin O may exert their effect by directly targeting the
endothelial cells [10]. This points towards endothelial
damage as a key event in the pathogenesis of bovine necro-
hemorrhagic enteritis. Indeed, in the present study antisera
which protected against C. perfringens-induced cytotoxicity
to bovine endothelial cells also offered protection against C.
perfringens-associated necrosis in an intestinal loop assay.
Moreover, the protective antisera were shown to inhibit the
activity of alpha toxin and perfringolysin O, which further
underscores the roles of these toxins in the pathogenesis of
bovine necrohemorrhagic enteritis. It can, however, not be
ruled out that antibodies induced against other substances
present in the vaccines also played a role in the protection
observed in the intestinal loop model.
Formaldehyde inactivation of C. perfringens toxins di-
minished their capacity to induce protective antibodies.
Antisera raised against L-lysine protected, formaldehyde
inactivated C. perfringens toxins were also not protective
in the intestinal loop model. This result is in disagree-
ment with previous studies showing high antigenicity,
low toxicity, and protection in mice that were immunized
with L-lysine protected, formaldehyde inactivated toxoid
and subsequently challenged with lethal doses of C. per-
fringens [19, 21]. In the present study we demonstrated
that vaccinations with C. perfringens toxins, either in their
native forms or as formaldehyde inactivated toxoids, all
resulted in high antibody responses as detected by ELISA.
However, only serum derived from animals immunized
with the native toxins offered protection against necrosis
in an intestinal loop assay. There is thus a discrepancy be-
tween the antibody titers against formaldehyde inactivated
C. perfringens toxins measured by ELISA and the protect-
ive capacity of these antibodies in the intestinal loop
model. Nevertheless, the value of vaccines based on
Fig. 3 C. perfringens-induced necrosis in experimentally infected intestinal loops in calves. a Representative histological section from an intestinal
loop without necrotic lesions. This loop was injected with C. perfringens in combination with antiserum to native C. perfringens toxins. b Representative
section from an intestinal loop from the same calf, showing hemorrhage and extensive necrosis of the villi. This loops was injected with C. perfringens
in combination with naïve immune serum
Table 2 In vitro neutralization of biological activities of alpha
toxin and perfringolysin O. Calves were immunized with either a
C. perfringens toxin preparation (native toxins), L-lysine protected,
formaldehyde inactivated C. perfringens toxins (L-lysine/formaldehyde
toxoid) or a commercial multivalent formaldehyde inactivated
clostridial vaccine
Inhibitory capacity (Mean ± SEM)
Antiserum Alpha toxin activitya PFO activityb
Native toxins 409.8 ± 5.75 48.0 ± 0.0
L-lysine/formaldehyde toxoid 80.47 ± 46.93 72.0 ± 24.0
Commercial formaldehyde vaccine 22.39 ± 2.17 18.0 ± 6.0
aNeutralization of 10 μg/ml alpha toxin. The inhibitory capacity of the
antiserum is expressed as the dilution that gives 50 % inhibition of the alpha
toxin activity
bNeutralization of 2 μg/ml perfringolysin O. The inhibitory capacity of the
antiserum is expressed as the highest dilution that inhibited perfringolysin
O-induced hemolysis
Alpha toxin activity was determined by measuring its lecithinase activity on egg
yolk lipoproteins. Perfringolysin O (PFO) activity was determined by measuring
the hemolysis of horse erythrocytes
Table 3 In vitro neutralization of C. perfringens cytotoxicity.
Calves were immunized with either a C. perfringens toxin
preparation (native toxins), L-lysine protected, formaldehyde
inactivated C. perfringens toxins (L-lysine/formaldehyde toxoid)
or a commercial multivalent formaldehyde inactivated clostridial
vaccine
Antiserum Inhibitory capacity (Mean ± SEM)
Native toxins 32.00 ± 0.0
L-lysine/formaldehyde toxoid 9.00 ± 7.0
Commercial formaldehyde vaccine 4.00 ± 0.0
The cytotoxicity of C. perfringens supernatant to primary bovine endothelial
cells was measured using a neutral red uptake (NRU) assay. The inhibitory
capacity of the antiserum is expressed as the highest dilution that yields 80 %
cell viability
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formaldehyde inactivated C. perfringens toxins has been
demonstrated for diseases associated with toxins other
than alpha toxin and perfringolysin O [22–25]. This sug-
gests that the protective immunogenicity of other C. per-
fringens toxins, such as, amongst others, NetB and epsilon
toxin, is not affected by formaldehyde inactivation.
Although the use of C. perfringens native toxins repre-
sents an efficient strategy for vaccine development, active
toxins cannot be regarded as safe. Therefore methods for
the development of toxoids other than formaldehyde inacti-
vation are needed. Possible strategies include the use of
genetically modified toxoids based on site-directed mutants
with reduced toxic activity or the use of immunologically
active fragments of the essential toxins. Immunization with
the carboxy-terminal domain of alpha toxin has previously
been shown to provide protection in a mouse model
against C. perfringens gas gangrene and may be a good
candidate for development of a vaccine against bovine
necrohemorrhagic enteritis [21, 26]. The identification of
the structural elements responsible for membrane inter-
action of perfringolysin O provides opportunities for the
development of non-toxic site-directed mutants as alterna-
tives for native perfringolysin O [27].
In order to obtain the ultimate evidence that vaccination
against C. perfringens toxins protects against bovine necro-
hemorrhagic enteritis, field trials need to be performed.
However, since necrohemorrhagic enteritis is a low inci-
dence disease, this would be a huge cost and more evidence
concerning the immune-protective potential of the antisera
is needed before considering this type of trial. Unfortunately,
no in vivo model to validate the protective immune-
potential of the candidate vaccines against bovine necrohe-
morrhagic enteritis is available. Niilo and colleagues were
able to induce a mild diarrhea in cattle inoculated intraduo-
denally or per os with C. perfringens type A cultures, but no
necrohemorrhagic enteritis was established [28]. Also we
were unable to develop a reliable model of bovine necrohe-
morrhagic enteritis after per os or intraduodenal administra-
tion of C. perfringens type A cultures (unpublished results).
Conclusion
This study showed that toxin-neutralizing antibodies
protect against C. perfringens challenge in an intestinal
loop model for bovine necrohemorrhagic enteritis.
Immunization of calves with either native or formalde-
hyde inactivated toxins resulted in a strong immune
response against alpha toxin and perfringolysin O, but
only antibodies raised against native toxins were protect-
ive in the intestinal loop model. Therefore it seems that,
at least for alpha toxin mediated diseases, antibody titers
detected by ELISA are not a guarantee for protection,
even if protection against the disease is antibody
mediated.
Methods
Vaccine preparation and immunization
C. perfringens toxin preparation (P4039, Sigma-Aldrich,
Bornem, Belgium) was either used as native toxin or
treated with formaldehyde to generate a formaldehyde
toxoid. Inactivation was obtained by adding a combin-
ation of 0.4 % formaldehyde solution (Sigma-Aldrich)
and 0.05 M L-lysine (Sigma-Aldrich) and incubation at
37 °C for two days. The addition of 0.05 M L-lysine has
previously been shown to preserve the antigenicity of
alpha toxin during toxoid formation [19]. Inactivation of
alpha toxin was confirmed by spotting 5 μl drops on 2 %
egg yolk Columbia agar plates (Oxoid, Wesel, Germany),
followed by incubation for 16 h at 37 °C [29]. Native and
formaldehyde inactivated toxins were formulated with
the adjuvant Quil A (Brenntag Biosector, Frederikssund,
Denmark) at a final concentration of 350 μg antigen and
750 μg Quil A in 1.5 ml phosphate buffered saline (PBS)
per animal and filter-sterilized using a 0.2 μm filter. A
standard formalin inactivated multivalent commercial vac-
cine was used according to the manufacturer’s instructions
(Covexin 10®, Zoetis, Louvain-la-Neuve, Belgium).
For immunization six 2-months old male Holstein
Friesian calves were used. The calves were purchased
from a local tradesman which collects dairy calves from
herds in Eastern Flanders. They were housed on straw
and received water and hay at libitum, and concentrates
adjusted to the body weight.
For each antigen, two calves were immunized subcuta-
neously in the neck. The calves received a primer vaccin-
ation at the age of two months, with booster
immunizations 14 and 28 days later. No strong adverse re-
actions were observed. Although no fever (>39.5 °C) was
induced, all calves experienced a mild hyperthermia for
two days following the vaccination. As described in the
drug information leaflet of the commercial vaccine, local-
ized swelling occurred at the site of injection. This effect
was more pronounced in the calves vaccinated with the
commercial formaldehyde inactivated clostridial vaccine
(7–10 cm diameter) as compared to the calves vaccinated
with either native toxins or the L-lysine protected, formal-
dehyde inactivated toxins (0–6 cm diameter). Blood sam-
ples were taken before primer vaccination and two weeks
after the final booster vaccination.
SDS-PAGE and Western Blot
The proteins present in the toxin preparation were visual-
ized on a 12 % SDS-PAGE followed by Coomassie Briliant
Blue staining (Sigma-Aldrich). For the Western Blot ana-
lysis, 16 μl of cell-free supernatants of the C. perfringens
strain JIR325 (10x concentrated using Vivaspin, Sartorium
Stedim Biotech GmbH, Goettingen, Germany) or 6 μg of
the C. perfringens toxin preparation were loaded on a 12 %
SDS-PAGE. The proteins from the gel were transferred to
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nitrocellulose membranes of 0.45 μm pore size. Non-
specific binding to the blots was blocked with 5 % skimmed
milk powder in PBS, followed by overnight incubation at
4 °C with a 1/500 dilution of the immune sera collected
two weeks after the final booster immunization. For this in-
cubation step, the sera of the 2 animals that were vacci-
nated with a given vaccine preparation were pooled. Blots
were washed with 0.1 % tween 20 in PBS and incubated for
1 h at room temperature with horseradish peroxidase-
labelled rabbit-anti-bovine IgG (Sigma-Aldrich). Blots were
developed with CN/DAB substrate kit (Thermo Fisher
Scientific, Rockford, USA). The test was performed in tripli-
cate. The specific immunoreactive protein bands were iden-
tified in the parallel-run Coomassie stained gel followed by
MALDI analysis.
Enzyme-linked immunosorbent assay
The immune response following vaccination was also
measured by ELISA using serum samples two weeks
after the final booster immunization.
Alpha toxin-specific antibody levels were determined
by the end-point dilution method using a blocking
ELISA (Clostridium perfringens alpha toxin serological
ELISA kit, Bio-X Diagnostics, Jemelle, Belgium). For
each ELISA, sera were used at a dilution 1:50 and assays
were performed in duplicate. The specific antibody level
of the immune serum was expressed as the percent in-
hibition (% inhib) by means of the following formula:
% inhib = [(OD neg – OD sample)/OD neg] * 100.
Perfringolysin O-specific antibody levels were mea-
sured using an indirect ELISA. Briefly, 96-well microtitre
plates (Nunc MaxiSorp, Thermo Fisher Scientific) were
coated with 20 μg recombinant perfringolysin O [30].
Non-specific binding was blocked with 1 % (w/v) bovine
serum albumin (Sigma-Aldrich) in PBS. Two-fold dilu-
tions of the sera ranging from a dilution of 1:50 to
1:51200 were added to the plates (100 μl of each dilu-
tion/well; in duplicate) and incubated for 2 h at 37 °C.
Plates were washed with 0.1 % (v/v) Tween 20 in PBS
and incubated for 1 h 30 min at 37 °C with horseradish
peroxidase-labelled rabbit-anti-bovine IgG (Sigma-Al-
drich). Bound conjugate was detected using the substrate
3,3′,5,5′-Tetramethylbenzidine (TMB) (Sigma-Aldrich).
The reaction was blocked with H2SO4 and the absorb-
ance was measured at 450 nm using a microplate reader
(Multiscan MS, Thermo Labsystems, Helsinki, Finland).
The end-point titer is expressed as the reciprocal of the
last dilution that gave a reading of 0.1U above back-
ground (precolostral neonatal bovine serum).
Intestinal loop model
To study the protection against C. perfringens-induced ne-
crosis provided by the antisera from calves vaccinated with
the vaccine preparations, four intestinal loop experiments
were performed. Intestinal loop experiments were per-
formed according to a previously described protocol using
4 healthy male Holstein Friesian calves, purchased from a
local tradesman which collects dairy calves from herds in
Eastern Flanders [20]. Briefly, the calves were anesthetized
and the small intestine was exteriorized. Per calf 80 intes-
tinal loops of approximately 10 cm were ligated in the je-
junum and a 5 cm space was left between the loops. Only
half of the loops were injected, thus each time leaving one
intervening loop to avoid leakage between sampled loops.
For each vaccine preparation individual pre- and post-
vaccination sera of 2 calves were used in two intestinal
loop experiments. Intestinal loops were inoculated with
20 ml of a wild-type strain (JIR325) in combination with
10 ml of 25 % commercial milk replacer suspended in
sterile NaCl solution, resulting in a total volume of 30 ml
which was the same across all treatments and control
loops. Prior to inoculation pre- or post-immune serum de-
rived from calves immunized with the different vaccine
preparations was added to the NaCl solution containing
milk replacer, to obtain a final concentration of 6 % serum
(v/v). In each calf five intestinal loops per test serum were
injected. Also an equal number of control loops without
addition of serum were injected either with C. perfringens
(positive control) or with sterile bacterial growth medium
(negative control). After injection of the loops, the abdo-
men was closed and the calves were maintained under
anesthesia. At 5-h post-inoculation intestinal biopsy sam-
ples were taken, after which the animals were euthanized.
Samples were fixed in 4 % phosphate buffered formalde-
hyde. They were embedded in paraffin wax, sectioned and
stained with hematoxylin-eosin. The sections were evalu-
ated in a blinded manner by a board certified pathologist
for presence of tissue necrosis (0 = absence of necrosis, 1
= necrotic lesions present).
In vitro neutralization and cytotoxicity tests
Neutralization of alpha toxin activity on egg yolk
lipoproteins in vitro
The alpha toxin activity was determined by its effect on
egg yolk lipoproteins as previously described [31].
Therefore, fresh egg yolk was centrifuged (10,000 × g for
20 min at 4 °C) and diluted 1:10 in PBS. The ability of
the sera to neutralize the alpha toxin activity was
assessed by pre-incubating a two-fold dilution series of
the sera (two wells per dilution) with a constant amount
of alpha toxin (10 μg/ml recombinant alpha toxin in PBS
solution) for 30 min at 37 °C prior to the addition of 10 %
egg yolk emulsion. Recombinant alpha toxin was expressed
in E. coli using the pBAD TOPO® TA Expression Kit
(Invitrogen, Paisley, UK) followed by purification onto a Ni-
sepharose column (His Gravitrap, GE Healthcare, Bucking-
hamshire, UK). After incubation of the plates at 37 °C for
1 h, the A620 was determined. Alpha toxin activity was
Goossens et al. BMC Veterinary Research  (2016) 12:101 Page 6 of 8
indicated by the development of turbidity which results in
an increase in absorbance. The inhibitory capacity of the
antiserum was determined by applying a Hill function to
the concentration-response data (GraphPad Prism 5,
GraphPad Software, San Diego, CA, USA) and expressed as
the dilution that inhibited 50 % of the alpha toxin activity.
The test was performed in duplicate.
Neutralization of perfringolysin O activity in vitro
Perfringolysin O (PFO) activity was determined by measur-
ing the hemolysis of horse erythrocytes using a doubling di-
lution assay as previously described [32]. The PFO titer is
the reciprocal of the last dilution which showed complete
hemolysis. Similar to the inhibition of the alpha toxin activ-
ities, the ability of sera to neutralize the PFO activity was
assessed by pre-incubating a two-fold dilution series of the
sera (two wells per dilution) with a constant amount of
perfringolysin O (2 μg/ml recombinant perfringolysin O).
Recombinant perfringolysin O was produced as previously
described [33]. The inhibitory capacity of the antiserum
was expressed as the highest dilution that inhibited perfrin-
golysin O induced hemolysis. The test was performed in
duplicate.
Endothelial cell cytotoxicity assay
Primary bovine umbilical vein endothelial cells (BUVEC)
were isolated from umbilical cord veins by an adaptation of
the method of Jaffe et al. as performed previously [10, 34].
The toxicity of C. perfringens supernatant towards cultured
bovine endothelial cells has been reported previously [10].
The ability of the antisera to neutralize the C. perfringens
cytotoxicity towards BUVECs was determined using a
Neutral Red Uptake assay (NRU) [35]. Therefore, a two-
fold dilution series of the sera (100 % - 0.4 %) prepared in
serum free cell culture medium was pre-incubated for
30 min at 37 °C with an equal amount of C. perfringens
supernatant. Cells were treated with 100 μl of these
supernatant-serum mixtures. The inhibitory capacity of the
antiserum was expressed as the highest dilution that yielded
80 % cell viability. As a positive control, cells were treated
with C. perfringens supernatant which was pre-incubated
for 30 min with serum free cell culture medium. Untreated
cells, incubated with serum free cell culture medium served
as a negative control. The test was performed in duplicate.
Statistical analysis
The 20 loops tested for each condition provided enough
statistical power to detect a 40 % reduction in the devel-
opment of necrotic lesions in the intestinal loop assay
(95 % confidence, 80 % power) (Winepiscope 2.0).
The protective effect of the antisera in the intestinal
loop assay as compared to the pre-immune sera and the
untreated control loops were determined by a Fisher’s
exact test (GraphPad Prism 5 software). Differences be-
tween groups were considered significant at p < 0.05.
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